# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Johnny Cash (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML004-SYN
- Date: 2026-08-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gideon Hale, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month diabetes review with glaucoma imaging. **S**

## History of present illness

Mr. Cash returns for his six-month review. Since midodrine was raised to 5 mg he rarely feels lightheaded, only if he stands quickly after lunch, and he has had no falls. He finished physical therapy and does the home exercises most days. The low-vision therapist reviewed his home lighting, and a second stair handrail is in place. His fasting home readings run 110 to 140 mg/dL, with none below 70. He has no scalp tingling or trouble passing urine and takes the last midodrine by mid-afternoon. He uses both eye drops daily and notices no change in his vision. The FIT kit from the wellness visit has not been returned. **S**

| Element | Detail |
|---|---|
| Interval change | Rarely lightheaded on midodrine 5 mg; no falls |
| Home glucose | Fasting 110 to 140 mg/dL; none below 70 |
| Rehabilitation | Physical therapy finished; home exercises; second stair handrail fitted |
| Vision | No change noticed |
| Open items | FIT kit not returned |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight down 1 kg; no fever |
| Eyes | Positive | Tunnel vision, unchanged; no eye pain |
| Cardiovascular | Negative | No fainting; lightheaded only on standing quickly after lunch |
| Respiratory | Negative | No cough or breathlessness |
| Genitourinary | Negative | No difficulty passing urine |
| Endocrine | Negative | No symptoms of low glucose |

6 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Sitagliptin 100 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 40 mg oral tablet, one tablet by mouth daily **S**
- Latanoprost 0.005% ophthalmic solution, one drop in each eye at bedtime **S**
- Dorzolamide 2% ophthalmic solution, one drop in each eye twice daily **S**
- Midodrine 5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PM **S**

## Allergies

- No known allergy **S**

## Objective

BP 134/74 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 96% on room air; weight 92.5 kg; BMI 26.2 kg/m². All vital signs are synthetic.

HbA1c: 7.3% (high); Sodium: 140 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 1.05 mg/dL; eGFR: 73 mL/min/1.73 m²; Glucose: 131 mg/dL (high); Urine albumin-creatinine ratio: 16 mg/g; Intraocular pressure, right eye: 14 mmHg; Intraocular pressure, left eye: 15 mmHg; Mean RNFL thickness by OCT, right eye: 60 um (low); Mean RNFL thickness by OCT, left eye: 57 um (low); Best-corrected visual acuity, right eye (ETDRS letters): 68 (low); Best-corrected visual acuity, left eye (ETDRS letters): 62 (low). All results are synthetic.

## Change since baseline

- HbA1c: 8.6% (high) at baseline, 7.3% (high) at this visit **S**
- Sodium: 138 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 1.04 mg/dL at baseline, 1.05 mg/dL at this visit **S**
- eGFR: 74 mL/min/1.73 m² at baseline, 73 mL/min/1.73 m² at this visit **S**
- Glucose: 186 mg/dL (high) at baseline, 131 mg/dL (high) at this visit **S**
- Urine albumin-creatinine ratio: 18 mg/g at baseline, 16 mg/g at this visit **S**
- Intraocular pressure, right eye: 22 mmHg (high) at baseline, 14 mmHg at this visit **S**
- Intraocular pressure, left eye: 24 mmHg (high) at baseline, 15 mmHg at this visit **S**
- Mean RNFL thickness by OCT, right eye: 61 um (low) at baseline, 60 um (low) at this visit **S**
- Mean RNFL thickness by OCT, left eye: 57 um (low) at baseline, 57 um (low) at this visit **S**
- Best-corrected visual acuity, right eye (ETDRS letters): 68 (low) at baseline, 68 (low) at this visit **S**
- Best-corrected visual acuity, left eye (ETDRS letters): 63 (low) at baseline, 62 (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert and well; walks with a cane |
| Eyes | Eye clinic today: pressure 14 mmHg right and 15 mmHg left; best-corrected acuity 68 letters right and 62 left; optic nerve appearance unchanged from intake |
| Cardiovascular | Regular rhythm; blood pressure 148/82 mmHg lying, 134/74 mmHg seated, and 120/70 mmHg after three minutes standing, without symptoms |
| Feet | Skin intact; no ulcers or calluses; sensory loss to the ankles unchanged; pedal pulses present |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Type 2 diabetes with diabetic autonomic neuropathy** (E11.43). HbA1c 7.3%, below his goal of 7.5%, with no hypoglycemia. Kidney screening normal: eGFR 73 and urine albumin-creatinine ratio 16 mg/g. **S**
   - Continue metformin 1000 mg twice daily and sitagliptin 100 mg daily.
   - HbA1c every six months now that he is at goal.
2. **Neurogenic orthostatic hypotension** (I95.1). Standing systolic pressure 120 mmHg on midodrine 5 mg, above the goal of 100, and no falls. Lying pressure 148/82 mmHg, with no supine hypertension. **S**
   - Continue midodrine 5 mg three times daily and the non-drug measures.
3. **Primary open-angle glaucoma, severe stage** (H40.1133). Eye pressures 14 and 15 mmHg. Nerve fiber layer thickness is unchanged (60 and 57 µm, against 61 and 57 at intake), acuity is stable, and the 24-2 fields show no new defect against intake, so the pressure check missed in the spring caused no measurable loss. **S**
   - Continue latanoprost and dorzolamide.
   - Eye clinic review in three to six months; OCT and fields every six months; add a 10-2 field test at the next field visit.
4. **Mild nonproliferative diabetic retinopathy** (E11.3293). No change reported by the eye clinic. **S**
   - Dilated retinal examination yearly.
5. **Hyperlipidemia** (E78.5). LDL 74 mg/dL three months ago, just above the goal below 70. **S**
   - Lipid panel with lipoprotein(a) at the annual review.
6. **Preventive care**. The hepatitis C antibody drawn at the last visit has no result on file, and the FIT kit has not been returned. **S**
   - Result requested from the laboratory.
   - Reminder given to return the FIT kit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HbA1c | Every 3 months until at goal or after a therapy change; every 6 months when stable | Completed today | 7.3%, at goal; repeat every six months |
| Laboratory | Basic metabolic panel and urine albumin-creatinine ratio | Yearly when eGFR is 60 or more and albumin is normal | Completed today | eGFR 73; potassium 4.5; urine albumin-creatinine ratio 16 mg/g. Repeated at six months because he takes full-dose metformin and midodrine, which the kidney clears |
| Laboratory | Lipid panel | Every 3 to 12 months until stable, then yearly | Due | LDL 74 three months ago; at the annual review with lipoprotein(a) |
| Laboratory | Vitamin B12 on metformin | Periodically on long-term metformin, especially with neuropathy | Due | 286 pg/mL at intake, low-normal with neuropathy; repeat at the annual review, with methylmalonic acid if still below 300 |
| Laboratory | ALT, AST, and platelets for FIB-4 | At diagnosis and yearly | Due | AST and a platelet count added to the annual tests after the gap noted at three months |
| Examination | Blood pressure, weight, and BMI | Every visit | Completed today | Seated 134/74 mmHg; weight 92.5 kg, down 3.5 kg since intake |
| Examination | Lying, seated, and standing blood pressure | Every visit | Completed today | Lying 148/82, standing 120/70 mmHg; goal of a standing systolic pressure of 100 or more met |
| Examination | Foot examination (inspection, pulses, monofilament) | Every visit with loss of protective sensation | Completed today | No ulcer; sensory loss unchanged |
| Examination | Dental examination | Yearly | Due | No dental examination on record; advised to see his dentist |
| Examination | Tonometry (eye pressure) | Every visit | Completed today | 14 mmHg right and 15 mmHg left |
| Examination | Best-corrected visual acuity | Each comprehensive eye examination | Completed today | 68 letters right and 62 left, against 68 and 63 at intake |
| Examination | Drop adherence, ocular surface, and systemic effects of glaucoma drops | Every visit | Completed today | Both drops used daily; no ocular surface irritation; no systemic effect |
| Imaging | OCT of the optic nerve and nerve fiber layer | Every 6 to 12 months; every 6 months in severe glaucoma | Completed today | 60 µm right and 57 µm left, against 61 and 57 at intake: no structural progression |
| Survey | Visual field (Humphrey 24-2) | Every 6 to 12 months | Completed today | No new defect against intake |
| Survey | Visual field (Humphrey 10-2) | In advanced disease, alongside the 24-2 | Deferred | Not done at intake or today, a deviation from the protocol for severe glaucoma. The 24-2 and OCT are stable, so loss near fixation is unlikely to have been missed; the eye clinic will add a 10-2 at the next field visit |
| Examination | Gonioscopy and corneal thickness | At the initial evaluation; repeat only with an unexplained pressure change | Not indicated | Baseline measures belong to the eye clinic's initial evaluation; the pressure response has been as expected |
| Survey | Hypoglycemia review and home glucose log | Every visit | Completed today | No readings below 70 mg/dL |
| Survey | Diabetes distress, anxiety (GAD-7), disordered eating, and social needs screens | Yearly | Due | Not yet done this year; at the annual review |
| Survey | Cognitive screen and fall risk | Yearly at 65 or older | Up to date | Mini-Cog 5 of 5 at intake; Timed Up and Go 14 seconds at the wellness visit |
| Survey | 10-year cardiovascular risk (PREVENT) | Yearly from 40 to 75 without cardiovascular disease | Not indicated | He already takes a high-intensity statin for diabetes with complications, so the score would not change treatment |
| Survey | Tobacco use | Every visit | Completed today | No tobacco use |
| Medication safety | Midodrine safety: lying pressure, timing, and urinary retention | Every visit on midodrine | Completed today | Lying 148/82 mmHg; no retention |
| Medication safety | Vaccination review | Yearly, and as doses fall due | Due | Recombinant zoster dose 2 is due within six months of dose 1, at his pharmacy, alongside the seasonal influenza vaccine; RSV and COVID-19 before the respiratory season; tetanus booster |
| Referral | Diabetes self-management education and medical nutrition therapy | At diagnosis, yearly, with new complications, and at care transitions | Referred | Not arranged in the first six months despite two medication changes, a deviation from the protocol. No harm resulted, since HbA1c reached goal without hypoglycemia. Referred today to an individual program with large-print materials because of his vision |
| Self-management | Exercise, diet, orthostatic measures, and foot self-care | Every visit | Completed today | Home exercises most days; smaller lunches; daily foot checks |

## Goal progress

- Reach an HbA1c below 7.5% without hypoglycemia by the six-month review. Outcome by 2026-08-14: HbA1c fell from 8.6% to 7.3% with no hypoglycemia. **S**
- No falls and a standing systolic pressure of 100 mm Hg or more by the six-month review. Outcome by 2026-08-14: No falls since the second visit; 134/74 seated and 120/70 standing on midodrine. **S**
- Lower intraocular pressure to 16 mm Hg or less in each eye by the three-month review. Outcome by 2026-05-29: Pressure 15 mm Hg right and 16 mm Hg left at three months. **S**
- LDL cholesterol below 70 mg/dL by the six-month review. Outcome by 2026-08-14: LDL 74 mg/dL at three months; recheck at the annual visit. **S**

## Guideline basis

- Standards of Care in Diabetes—2025 (2025), American Diabetes Association
- Primary Open-Angle Glaucoma Preferred Practice Pattern (2025), American Academy of Ophthalmology
- CMID: Clinical Monitoring Intelligence Database, diabetes, glaucoma, and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Eye clinic review in three to six months. Diabetes review in six months with HbA1c. Annual review with lipids, lipoprotein(a), vitamin B12, AST, platelet count, and the yearly screens. **S**

